What are your thoughts on the ABBV earnings today?
I don't think they released earnings, but only announced a $150m charge that will hit the quarter. Not a big deal.
The big deal is biosim competition against Humira:
Argus has downgraded AbbVie (NYSE:ABBV) to hold from buy as it faces biosimilar competition for its blockbuster drug Humira (adalimumab), which accounts for more than 40% of sales.
Analyst Jasper Hellweg said that although management has stated growth in sales of Skyrizi (risankizumab) and Rinvoq (upadacitinib) will help offset the decline in Humira revenue, it may take until 2027 until those two drugs combined surpass Humira peak sales.
In addition, in its Q4 2022 earnings call, the company said that it likely won't see robust sales growth until 2025.
Hellweg said that AbbVie's (ABBV) aesthetics portfolio, namely Botox and Juverderm, has shown growth, as has the atypical antipsychotic Vraylar (cariprazine).
Amgen (AMGN) launched the first Humira biosimilar in the US, Amjevita (adalimumab-atto), in late January.
-----
While Skyrizi and Rinvoq are growing nicely, I would be surprised if ABBV only suffers the projected 37% decline in Humira sales. There are 8-9 competitors coming out this year. Even if Humira holds onto market share, its net price will erode.
ABBV is a great company, but I would view it as a hold, not a buy until the biosim dust settles.